OMLYCLO Shakes Up U.S. Biologic Market as Key Player
Ah, the pharmaceutical game is shifting again, and this time Celltrion USA's putting their chips down with OMLYCLO, the shiny new omalizumab biosimilar. Here we see a product that's not just approved but interchangeable with XOLAIR, making it a front-runner in the allergic and inflammatory conditions battleground. If you're a patient or a provider navigating these murky...
Continue Reading